AXSM's Progressing Migraine Drug NDA: Stock Sees Immediate Boost
![AXSM's Progressing Migraine Drug NDA: Stock Sees Immediate Boost](https://investorshangout.com/images/blog/ihnews-AXSM%27s%20Progressing%20Migraine%20Drug%20NDA%3A%20Stock%20Sees%20Immediate%20Boost.jpg)
Axsome Therapeutics Secures FDA NDA Acceptance for Migraine Treatment
Axsome Therapeutics, Inc. (NASDAQ: AXSM) has achieved a significant milestone as the FDA accepted its resubmitted new drug application (NDA) for the innovative treatment AXS-07, aimed at providing relief for acute migraine episodes. This move opens the door for potential approval, sparking renewed interest in the company's stock.
The FDA has set a timeline for a final decision, anticipated by January 31, 2025, and has categorized this NDA resubmission as a Class 2 resubmission, indicating a more rigorous review process.
In response to the announcement, shares of AXSM experienced a notable uptick of 6.6% on September 4, reflecting market optimism. Year to date, Axsome’s stock price has increased by 20.1%, contrasting with a slight decline in the broader industry, which showcased a decrease of 0.9%.
Addressing Prior Concerns: The Journey to Resubmission
Initially, the FDA had issued a complete response letter regarding the first NDA for AXS-07 in April 2022, citing issues related to its chemistry, manufacturing, and controls. Following this, Axsome diligently worked to address these concerns, completing the NDA resubmission in the second quarter of 2024. Encouragingly, the FDA did not request additional data regarding safety or efficacy in this latest round, further strengthening the prospects of gaining approval for AXS-07.
Diversifying Axsome's Product Lineup
If approved, AXS-07 will complement Axsome's existing commercial products, which currently include Auvelity (AXS-05) for major depressive disorder and Sunosi (solriamfetol) for narcolepsy. The approval of AXS-07 would significantly diversify Axsome’s therapeutic offerings.
Auvelity, launched in 2022, has already demonstrated a positive sales trajectory, generating an impressive $118.4 million in revenue during the first half of 2024, marking an increase of 172.8% compared to the previous year. This growth underscores the strong demand for the medication in the market.
On the other hand, Sunosi, acquired from Jazz Pharmaceuticals (NASDAQ: JAZZ), received FDA approval in 2019 as a treatment for narcolepsy. After its commercial launch in May 2022, Sunosi’s sales also showed positive growth, contributing $42.2 million in net product sales during the first half of 2024, which represents a year-over-year increase of 35.2%.
Current Stock Position and Market Comparisons
As it stands, Axsome holds a Zacks Rank of #3 (Hold), suggesting a neutral outlook based on market analyses. However, investors looking for more robust opportunities may want to consider other well-ranked biotech stocks.
Companies like Krystal Biotech, Inc. (NASDAQ: KRYS) and Fulcrum Therapeutics, Inc. (NASDAQ: FULC) currently possess Zacks Rank #1 (Strong Buy), indicating favorable market conditions and investor confidence. Recent performance indicates that Krystal Biotech's earnings estimates for 2024 have increased significantly, showcasing a rise from $1.98 to $2.38. Meanwhile, shares have surged by 50.6% this year.
Similarly, Fulcrum Therapeutics has narrowed its projected losses for 2024 and witnessed its share prices grow by 22.2% year to date, reflecting positive growth trends that have piqued investor interest.
Looking Ahead: Future Prospects for AXSM
As Axsome Therapeutics proceeds with its potential milestones concerning AXS-07, the company’s trajectory promises interesting developments in the pharmaceutical landscape. With two marketed products already contributing to revenue and the possibility of a third, Axsome is positioning itself for continued growth and innovation within the treatment of neurological disorders.
Frequently Asked Questions
What is AXS-07, and what does it treat?
AXS-07 is a medication developed by Axsome Therapeutics intended for the acute treatment of migraine episodes.
When is the FDA expected to make a decision on AXS-07?
The FDA is expected to provide a final decision regarding AXS-07 by January 31, 2025.
How has AXSM's stock performed recently?
AXSM's stock increased by 6.6% following the FDA's acceptance of the NDA resubmission, and it has rallied 20.1% year to date.
What other products does Axsome Therapeutics have on the market?
Axsome currently markets Auvelity for major depressive disorder and Sunosi for narcolepsy.
What are the other biotech stocks to watch?
Investors may look at Krystal Biotech (KRYS) and Fulcrum Therapeutics (FULC), both currently holding strong rankings and positive growth forecasts.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Related Articles
- Growth Insights on Contact Lenses Market to Boost Opportunities
- Brazil Stock Market Report: Key Movements and Insights
- Market Dynamics: Canadian Stocks Dip with Sector Overviews
- U.S. Stock Market Closes Lower Amid Sector Fluctuations
- Why Box (NYSE: BOX) is a Hot Stock Right Now for Investors
- Teladoc Health Welcomes Key Executive with Stock Award
- ORIC Pharmaceuticals Grants Stock Options to New Employees
- NewAmsterdam Pharma Boosts Staff with Incentive Stock Options
- Insightful Options Movement in Newmont Mining Stock
- Key Cannabis Stock Performers Highlighted for Early September
Recent Articles
- Westhaven Gold Secures Venture Approval for Talisker Claims
- Elevating Online Safety: Wondershare FamiSafe 8.0 Unveiled
- August Jobs Data Signals Labor Market Stabilization
- Court Ruling Declares THC-O-Acetate Legal, Opposes DEA View
- VanEck Halts Ethereum ETF Due to Key Operational Challenges
- Why Cloud-Based Commercial Lending Software is a Game-Changer?
- Anticipating a Strong Comeback for Defense Metals Stock
- Exploring Recent Bullish Trends in AT&T Options Trading
- Exploring Recent Options Trends for Monolithic Power Systems
- Insights on Recent Options Activity for Southwest Airlines
- Upcoming Housing Announcement Set to Impact Communities
- Construction Begins on Luxurious Rosewood Residences
- TSMC Achieves Production Milestones at Arizona Plant
- New Social Housing Initiative Unveiled in Community Support
- Understanding NNN REIT's Short Interest Trends Effectively
- Discover the Profitable Journey of Investing in Watsco Stock
- Insights into Houlihan Lokey's Rising Short Interest Trends
- Ten Years of Growth: The Success Story of Celsius Holdings
- Procore Technologies Short Interest Insights and Trends
- Idaho's Stibnite Gold Project: A Secure Antimony Future
- Market Update: Argan Shares Surge Amid Volatile Trading
- Newcore Gold Elevates Capital Through Expanded Financing Deal
- Exciting Developments at Rosewood Residences by The Ronto Group
- Powell Max LTD Successfully Completes Initial Public Offering
- Big Fogg's Innovative Cooling Solutions Shine at U.S. Open
- Crew Launch Set for NASA Expedition 71 to Space Station
- Navigating Retirement Finances: Advice Everyone Needs
- XPeng Inc. Makes Waves with Flying Car Pre-Orders
- Luvindow Launches Revolutionary Window Technology at Summit
- METZ Showcases Cutting-Edge Innovations at IFA 2024
- The Jim Henson Company's Exciting New Series Featuring Sports
- Exploring the Enigmatic Europa: NASA's Upcoming Mission
- Tiff's Treats Expands Cookie Delivery in Kansas with New Locations
- New Community Center Launches with Innovative ICF Design
- Breakthrough Diagnostic Tools by GEARWRENCH for Mechanics
- Wondershare FamiSafe 8.0 Unveils Innovative Features for Security
- Advisor Credit Exchange Earns Prestigious Industry Award
- AoChuang Holdings Announces Exciting IPO Plans for Investors
- Baidu's Options Trading Insights: A Closer Look
- Smart Money Moves: Insights into McDonald's (MCD) Options Market
- DoubleVerify's New Tool Enhances Political News Advertising
- Analyzing Recent Options Activity of Icahn Enterprises
- Investing Insights: Unpacking PayPal Holdings Options Trends
- Understanding MercadoLibre's Options Activity and Market Trends
- The Importance of Regular Financial Reviews for Business Stability
- Investing in Dell Technologies: A Remarkable Growth Story
- Investing in Vertex Pharmaceuticals: 20 Years of Growth Insight
- Understanding the Impact of Wall Street's Stories on Investments
- JP Morgan's Insights on Specialty Pharma: What Investors Need to Know
- Moderna's Mpox Vaccine Trial Shows Promising Results Over Jynneos